Construction of a 124I-Labeled Specific Antibody for the Noninvasive Detection of Mesothelin-Overexpressing Tumors.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.2c00342
Abstract: Mesothelin (MSLN) is a molecular biomarker of many types of solid tumors, such as mesothelioma, pancreatic cancer, and colon cancer. Owing to the significant difference in expression between cancer cells and normal cells, mesothelin has… read more here.
Keywords: mesothelin; anti msln; 124i anti; msln ... See more keywords
Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager
Sign Up to like & getrecommendations! Published in 2025 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2024-010063
Abstract: Background The glycosylphosphatidylinositol-anchored cell surface protein mesothelin (MSLN) shows elevated expression in many malignancies and is an established clinical-stage target for antibody-directed therapeutic strategies. Of these, the harnessing of autologous patient T cells via engineered… read more here.
Keywords: anti msln; labc 13f08; cell secreted; msln ... See more keywords
Challenges of Anti-Mesothelin CAR-T-Cell Therapy
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15051357
Abstract: Simple Summary In recent years, chimeric antigen receptor (CAR)-T-cell therapy has achieved good results in hematological malignancies. Clinical trials on anti-MSLN CAR-T cells have shown that they have a high safety profile but limited efficacy.… read more here.
Keywords: car; anti msln; cell therapy; car cell ... See more keywords